---
title: "Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026) | PepTracker Pro Blog"
url: https://peptrackerpro.com/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026
description: "Antibodies barely cross into the brain - which is why anti-amyloid Alzheimer's drugs need big infusions and still cause brain swelling. Roche's trontinemab flips the problem: it hitches a plaque-clearing antibody to a transferrin-receptor 'shuttle' that ferries it across the blood-brain barrier. Early data show some of the fastest, deepest amyloid clearance yet - with strikingly little ARIA. Here's what trontinemab is, how the Brainshuttle works, and why TRONTIER 1/2 and the new PrevenTRON prevention trial are the readouts to watch."
lang: en
---

Skip to main content

**Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer)

Research & Compounds

Research & Compounds

# Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026)

PepTracker Pro Research Team August 25, 2026 8 min read

## Table of Contents

- The problem: the brain is a walled garden
- The trick: a shuttle that rides the iron highway
- Why that matters: more brain, less drug, less ARIA
- The early data: fast, deep amyloid clearance
- The safety headline: ARIA under 5%
- The pivotal test: TRONTIER 1 and TRONTIER 2
- Going upstream: the PrevenTRON prevention trial
- Bigger than Alzheimer's: a platform to watch
- How it fits PepTracker Pro's neuro coverage
- Bottom line and cautions

## The problem: the brain is a walled garden

The blood-brain barrier is superb at keeping large molecules out - including therapeutic antibodies. Only about 0.1 to 0.3% of an intravenously infused antibody actually reaches the brain. For Alzheimer's, that means the approved anti-amyloid antibodies (lecanemab and donanemab) have to be given at high, repeated doses to scrub amyloid plaques out of the brain, and even then they carry a meaningful risk of ARIA - amyloid-related imaging abnormalities, the brain swelling (ARIA-E) and micro-bleeding (ARIA-H) that show up on MRI and can occasionally be serious. Roche's trontinemab was designed to solve the delivery problem at its root.

## The trick: a shuttle that rides the iron highway

Trontinemab (development codes RG6102 / RO7126209) is built on Roche's 'Brainshuttle' platform. It is a 2+1 bispecific antibody: two arms grab amyloid-beta plaques (these arms come from Roche's earlier antibody gantenerumab), and a third piece grabs the transferrin receptor 1 (TfR1) on the cells that line the blood-brain barrier. TfR1 normally ferries iron-loaded transferrin into the brain; by latching onto it, trontinemab hitches a ride across the barrier through the same door - a process called receptor-mediated transcytosis. Cleverly, it binds TfR1 with just one arm (monovalently), which avoids jamming the receptor and lets the natural transport cycle keep working. The net effect: far more antibody gets into the brain per dose.

## Why that matters: more brain, less drug, less ARIA

Getting more antibody into the brain at a lower systemic dose isn't just elegant - it may change the safety equation. Much of the ARIA seen with conventional anti-amyloid antibodies is thought to relate to how they engage plaques in and around blood vessels at high doses. By concentrating the antibody where it's needed and using less of it, trontinemab appears to clear plaques hard while provoking far less brain swelling. That combination - deep clearance with low ARIA - is exactly what the field has been chasing.

## The early data: fast, deep amyloid clearance

In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), monthly intravenous trontinemab produced striking results. At the 3.6 mg/kg dose, mean amyloid burden fell by roughly 107 centiloids after 28 weeks - among the fastest and deepest reductions reported for any anti-amyloid antibody. About 91 to 92% of participants dropped below the 24-centiloid threshold that defines amyloid 'positivity,' and roughly 72% reached deep clearance below 11 centiloids. At AAIC 2026, Roche reported that these reductions were maintained across a one-year open-label extension.

## The safety headline: ARIA under 5%

The most talked-about number is the ARIA rate. Across the 1.8 and 3.6 mg/kg cohorts, ARIA-E (the swelling form) was seen in fewer than 5% of participants. For context, the approved antibodies report roughly 13% (lecanemab) and 24% (donanemab). If that low rate holds up in larger trials, it could mean less intensive MRI monitoring and a wider pool of patients who can be treated safely - including groups, like ApoE4 carriers, who face higher ARIA risk with existing drugs. Important caveat: ARIA can still happen, and larger trials are needed to confirm the profile.

## The pivotal test: TRONTIER 1 and TRONTIER 2

Biomarker clearance is promising, but the question that matters is whether removing plaque this aggressively actually slows the disease. To answer it, Roche launched two identically designed Phase 3 trials - TRONTIER 1 and TRONTIER 2 - enrolling about 1,600 people with early symptomatic Alzheimer's disease across 18 countries, beginning in 2025. Their dosing was informed by modeling from the Brainshuttle AD study. These trials will measure cognition and function, not just PET scans - the real bar for approval and for patients.

## Going upstream: the PrevenTRON prevention trial

At the 2026 Alzheimer's Association International Conference (AAIC) in London, Roche went a step further and unveiled PrevenTRON, a Phase 3 prevention trial. Instead of treating people who already have symptoms, PrevenTRON will enroll 1,600 cognitively unimpaired individuals who are at high risk - identified by elevated plasma p-tau217, a blood marker of early Alzheimer's pathology. The primary endpoint is time to clinical progression. The logic: if you can clear amyloid deeply and safely, maybe you can intervene before symptoms ever start. It's an ambitious bet that only makes sense because the Brainshuttle safety profile looks gentle enough to use in people who feel fine.

## Bigger than Alzheimer's: a platform to watch

Even setting aside Alzheimer's, trontinemab is a landmark test of an idea with huge reach: actively shuttling large molecules across the blood-brain barrier. If receptor-mediated transcytosis reliably delivers an antibody deep into the brain in humans, the same trick could carry other antibodies, enzymes and biologics into the central nervous system for conditions from Parkinson's to rare enzyme-deficiency diseases. That's why neurologists, drug developers and investors are watching trontinemab not just as one drug, but as a proof-of-concept for a whole delivery strategy.

## How it fits PepTracker Pro's neuro coverage

Trontinemab sits alongside other brain-focused compounds profiled here that approach cognition and neuroprotection from different angles: davunetide, a tau-stabilizing neuroprotective peptide; the mitochondrial-derived peptide humanin; the longevity protein klotho, studied for brain aging and cognition; the cognition peptide dihexa; and the neurotrophic mixtures cerebrolysin and the peptide P21. Most of those are small peptides acting on neurons or their support systems; trontinemab is a large engineered antibody whose novelty is less about a new target than a new way in - through the blood-brain barrier itself.

## Bottom line and cautions

Trontinemab is an investigational anti-amyloid antibody - not an approved medicine and not a supplement. Any product sold under its name outside a clinical trial is unverified and unsafe. Its early data are genuinely exciting: some of the deepest amyloid clearance yet reported, with ARIA rates far below approved drugs, thanks to a transferrin-receptor shuttle that smuggles it across the blood-brain barrier. But amyloid clearance is a biomarker, not a cure: whether it slows or prevents cognitive decline rests on the pivotal TRONTIER 1/2 trials and the PrevenTRON prevention study. For now, trontinemab is one of the most important things happening in Alzheimer's drug development - and a template for getting biologics into the brain. This article is educational and not medical advice.

Ready to track your peptide research?

Open PepTracker Pro (https://app.peptrackerpro.com/)

PepTracker Pro Research Team

The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.

## Citations

1. [1] Trontinemab Phase 3 Alzheimer Trials to Launch Following Promising Amyloid Clearance Data - Patient Care Online Source (https://www.patientcareonline.com/view/trontinemab-phase-3-alzheimer-trials-to-launch-following-promising-amyloid-clearance-data)
2. [2] Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab - NeurologyLive Source (https://www.neurologylive.com/view/roche-unveils-preventron-phase-3-prevention-trial-trontinemab-cognitively-unimpaired-individuals-high-risk-alzheimers)
3. [3] Roche presents new data in Alzheimer's disease at AAIC (July 7, 2026) Source (https://www.roche.com/media/releases/med-cor-2026-07-07)
4. [4] Roche Is Back in Alzheimer's as Latest Antibody Clears Amyloid Plaques - BioSpace Source (https://www.biospace.com/drug-development/roche-is-back-in-alzheimers-as-latest-antibody-clears-amyloid-plaques)
5. [5] Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain (mAbs, 2023) - PubMed Source (https://pubmed.ncbi.nlm.nih.gov/37823690/)
6. [6] Trontinemab - ALZFORUM therapeutics Source (https://www.alzforum.org/therapeutics/trontinemab)

**Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer → (https://peptrackerpro.com/research-disclaimer)

## Related Articles

Research & Compounds cover image (https://peptrackerpro.com/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026)

Research & Compounds ### Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026) (https://peptrackerpro.com/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026)

Klotho is a longevity hormone your body makes naturally. A single low-dose injection improved memory in aged monkeys, and a Phase 1 trial is now testing it in older adults. Here's what the evidence shows — and why klotho is a large protein, not a peptide you can buy.

PepTracker Pro Team

June 16, 2026 9 min read

Read (https://peptrackerpro.com/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026)

Research & Compounds cover image (https://peptrackerpro.com/blog/humanin-mitochondrial-derived-peptide-longevity-neuroprotection-june-21-2026)

Research & Compounds ### Humanin: The Mitochondrial-Derived Peptide Behind the 2026 Longevity-Biomarker Buzz (June 21, 2026) (https://peptrackerpro.com/blog/humanin-mitochondrial-derived-peptide-longevity-neuroprotection-june-21-2026)

Humanin is an endogenous peptide encoded by your mitochondria that protects neurons, declines with age, and runs high in centenarians. Here is what the research actually shows in 2026 — and what it does not.

PepTracker Pro Team

June 21, 2026 9 min read

Read (https://peptrackerpro.com/blog/humanin-mitochondrial-derived-peptide-longevity-neuroprotection-june-21-2026)

Research & Compounds cover image (https://peptrackerpro.com/blog/davunetide-nap-microtubule-tau-neuroprotection-adnp-syndrome-june-22-2026)

Research & Compounds ### Davunetide (NAP): The Tau-Targeting Microtubule Peptide Getting a Second Act in 2026 (June 22, 2026) (https://peptrackerpro.com/blog/davunetide-nap-microtubule-tau-neuroprotection-adnp-syndrome-june-22-2026)

Davunetide is an eight-amino-acid peptide that stabilizes microtubules and lowers tau phosphorylation. It failed a major tauopathy trial — and in 2026 it is back, aimed at a rare genetic disease. Here is what the research actually shows.

PepTracker Pro Team

June 22, 2026 9 min read

Read (https://peptrackerpro.com/blog/davunetide-nap-microtubule-tau-neuroprotection-adnp-syndrome-june-22-2026)

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "name": "PepTracker Pro",
    "url": "https://peptrackerpro.com",
    "logo": "https://peptrackerpro.com/favicon.png",
    "description": "Evidence-based educational resource dedicated to improving peptide research literacy.",
    "contactPoint": {
      "@type": "ContactPoint",
      "email": "hello@peptrackerpro.com",
      "contactType": "customer support"
    },
    "sameAs": []
  },
  {
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026)",
    "description": "Antibodies barely cross into the brain - which is why anti-amyloid Alzheimer's drugs need big infusions and still cause brain swelling. Roche's trontinemab flips the problem: it hitches a plaque-clearing antibody to a transferrin-receptor 'shuttle' that ferries it across the blood-brain barrier. Early data show some of the fastest, deepest amyloid clearance yet - with strikingly little ARIA. Here's what trontinemab is, how the Brainshuttle works, and why TRONTIER 1/2 and the new PrevenTRON prevention trial are the readouts to watch.",
    "datePublished": "2026-08-25",
    "dateModified": "2026-08-25",
    "author": {
      "@type": "Organization",
      "name": "PepTracker Pro Research Team",
      "url": "https://peptrackerpro.com"
    },
    "publisher": {
      "@type": "Organization",
      "name": "PepTracker Pro",
      "logo": {
        "@type": "ImageObject",
        "url": "https://peptrackerpro.com/favicon.png"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://peptrackerpro.com/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026"
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://peptrackerpro.com"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Blog",
        "item": "https://peptrackerpro.com/blog"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026)",
        "item": "https://peptrackerpro.com/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026"
      }
    ]
  }
]
```